The FDA has granted Orphan Drug designation to TPST-1495, dual receptor inhibitor of prostaglandin signaling, for the treatment of familial adenomatous polyposis.

Data-driven clustering reveals distinct obesity phenotypes with unique clinical, behavioral, microbiome features, and differential GLP-1 responses.